

January 15, 2024

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001**

**To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

Sub:- Board Meeting

We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, January 23, 2024, inter alia, to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December, 2023.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its 'designated persons' regarding the closure of the Trading Window from December 31, 2023 to January 25, 2024 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the third quarter and nine months ended December 31, 2023.

The above is for your information.

Thanking you.

Yours faithfully,
For Glenmark Life Sciences Limited

**Rudalf Corriea
Company Secretary and Compliance officer**

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com